InnoCare Pharma (HKG:9969) recorded an attributable profit of 642.5 million yuan in the year 2025, compared with an attributable loss of 440.6 million yuan a year prior, according to a Wednesday Hong Kong bourse filing.
Earnings per share stood at 0.38 yuan for the period, compared with a loss per share of 0.26 yuan in the previous fiscal year.
The pharmaceutical company's revenue surged 135% to 2.37 billion yuan from 1.01 billion yuan previously, mainly due to strong drug sales growth and licensing revenue from collaborations with Zenas Biopharma and Prolium.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments